POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 35 / 2021

Date of preparation:2021-05-13Abbreviated name of the Issuer:MABION S.A.

Subject matter: Changes in the composition of the Company's Management Board and Supervisory Board

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

The Management Board of Mabion S.A. ("Company") hereby informs that today, Mr. Krzysztof Kaczmarczyk has tendered his resignation from the position of Chairman and Member of the Company's Supervisory Board. At the same time the Supervisory Board of the Company adopted today a resolution to appoint Mr. Krzysztof Kaczmarczyk as President of the Company's Management Board for the first joint term of office, effective as of 14 May 2021.

The aforementioned resolution is a result of the today's dismissal, by the Company's Supervisory Board, of Mr. Dirk Kreder from the position of President of the Company's Management Board. The resolution on the dismissal came into force upon its adoption. At the same time, the Supervisory Board extends its gratitude to Mr. Dirk Kreder for his contribution to the development of the Company, and in particular for leading the Company through the process of implementing a new registration strategy for MabionCD20.

The main objective set by the Supervisory Board for Mr. Krzysztof Kaczmarczyk is to effectively carry out the process of acquiring a strategic investor, of which the Company informed in Current Report no. 3/2021 of 27 January 2021.

After the personal changes in the Management Board, the allocation of key areas / tasks and competences in the Company at the Management Board level is as follows:

- Krzysztof Kaczmarczyk - President of the Management Board, CEO - cooperation with Novavax, Inc. and managing the process of acquiring a strategic investor,

- Sławomir Jaros - Member of the Management Board, COO and CSO - scientific area of all projects, MabionCD20 project,

- Adam Pietruszkiewicz - Member of the Management Board - cooperation with Novavax, Inc. (conducting the antigen project to arrive at a vaccine candidate) and new strategic and development projects,

- Grzegorz Grabowicz - Member of the Management Board, CFO - financing strategy.

At the same time, the Supervisory Board of the Company adopted today a resolution to elect a Member of the Supervisory Board - Mr. Robert Koński as Chairman of the Supervisory Board of the Company.

Mr. Krzysztof Kaczmarczyk is a graduate of the Warsaw School of Economics with a major in Finance and Accounting, and a former student at the University of Warsaw, majoring in International Relations.

Mr. Krzysztof Kaczmarczyk possesses extensive experience in the capital market. In the years 2006-2020, he served as member of the supervisory boards of over thirty companies listed on the Warsaw Stock Exchange. He participated in the processes aimed at acquiring strategic investors for companies such as: Polish Energy Partners, Robyg, Integer, Magellan, or CP Energia. In 2016-2019, he worked as Advisor to the Management Board of KGHM Polska Miedź S.A. In 2012 to 2015, he served as Deputy President of the Management Board for Strategy and Development at Emitel, the leading operator of terrestrial broadcasting network in Poland. In 2010-2011, he worked for a Swiss investment bank, Credit Suisse, in Poland. In 2008-2010, Mr. Krzysztof Kaczmarczyk held various management Division. In 1999-2008, he worked for Deutsche Bank in Poland, where he held the position of Deputy Head of the Stock Market Analysis Department and Stock Market Analyst - Central and Eastern Europe.

Mr. Krzysztof Kaczmarczyk, in accordance with the statement submitted by him, does not run any business competitive to the activities of the Company, does not participate in a competitive company as a partner in a partnership or a capital company, does not participate in a competitive legal person as a member of its bodies and is not listed in the Register of Insolvent Debtors kept pursuant to the Act on the National Court Register.